Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Our mission is to discover, develop and commercialize therapies and diagnostics to combat cancer and other diseases. We are dedicated to providing advanced healthcare solutions that have the potential to extend lives, give hope and improve quality of life.

Our vision is to be a leader in the development of innovative medical therapies and diagnostics that will enable us to move towards a future of personalized medicine, where treatments are tailored to the specific needs of each individual patient.

Anixa has earned numerous accolades in the biotechnology field, including being awarded the ‘Best New Company’ award from Scientific American in 2016 and being honored by FierceBiotech as one of the ‘Top 10 Biotechs to Watch’ in 2018.